Butterfly Network - UBS Global Healthcare Conference - BUTTERFLY NETWORK INC

Financial Performance:

• Revenue growth is driven by a shift toward recurring revenue streams from software subscriptions and embedded chip licensing, moving away from the previous $160M annual burn rate experienced three years ago.
• The company has transitioned to a stronger balance sheet with significantly reduced cash burn, recently placing a shelf registration statement to maintain optionality for future capital needs.
• Gross margins remain robust, with the potential for meaningful cash flow generation as hardware and software revenue models mature.
• Enterprise deals now feature multi-year (3-5 year) software contracts, resulting in Total Contract Values (TCV) in the six to seven figures, though revenue recognition is smoothed over the implementation period.
• The business model is evolving to include a "forever" hardware revenue stream and royalty streams from licensing partners, creating a high-leverage multiplier effect on future earnings.

Guidance and Future Outlook:

• Management anticipates that revenue from the semiconductor licensing and embedded chip business will eventually dwarf the traditional point-of-care ultrasound (POCUS) business within the next couple of years.
• The company expects to sign its first non-healthcare deal imminently, expanding into industrial applications (material stress testing for aerospace/bridges), underwater exploration, and military security.
• Next quarter will see the launch of the fourth-generation semiconductor, offering image quality superior to standard handheld POCUS devices, aimed at displacing legacy crystal-based technology.
• Future growth strategy includes aggressive organic development in new markets and potential M&A to accelerate capabilities, leveraging the improved balance sheet.

Business Segments and Product Lines:

• Point-of-Care Ultrasound (POCUS): Core business focusing on training medical students and upskilling first responders via AI-guided acquisition tools to reduce the learning curve; currently used by ~80% of US medical schools.
• Home & Community Care: A new service-based segment where Butterfly deploys devices and software at no upfront cost to risk-bearing providers (e.g., skilled nursing facilities), charging per scan to reduce hospital readmissions and lower costs of care.
• Enterprise Software (Compass): Middleware solution enabling EMR integration, DICOM compatibility, and revenue cycle management; addresses the 70% of images historically lost in non-hospital systems and drives large enterprise deployments.
• Semiconductor Licensing: Platform licensing of the infinitely programmable semiconductor chip to over a dozen partners across healthcare (HIFU, whole-body imaging), robotics, and industrial sectors; includes one exclusive whole-body imaging partnership.

Market and Competitive Landscape:

• The market is shifting from specialized ultrasonographer-dependent care to a "stethoscope model" where all clinicians can acquire images, supported by AI and improved semiconductor technology.
• Butterfly leverages a "garden" of 33 AI partners integrating with their ecosystem, creating a network effect that competitors cannot easily replicate.
• Competitive advantage is protected by a 15-year head start, 700+ patents, and a manufacturing partnership with TSMC; the upcoming 4th-gen chip is positioned to render legacy analog crystal technology obsolete.
• Adoption is accelerating in enterprise settings as hospitals seek to capture previously undocumented clinical data and automate billing, moving beyond siloed departmental purchases to health-wide deployments.

Risks and Challenges:

• Revenue Recognition Timing: Large enterprise contracts involve long implementation cycles, delaying immediate revenue recognition despite high TCV.
• Partner Secrecy: Key revenue drivers from embedded chip licenses are confidential; partners often forbid public disclosure of deals, making it difficult for investors to quantify the "show me" stage of this segment.
• Adoption Velocity: While the long-term vision of universal imaging is strong, short-term financial performance relies on compressing a 20-year educational timeline into a few years through AI and training.
• Competition: Management acknowledges that as the market grows, new entrants may emerge, though they plan to maintain the lead through continuous iteration (quarterly software/hardware updates).

Management Commentary and Tone:

• CEO Joe DeVivo projects high confidence, describing the company as being at the convergence of semiconductor improvement, AI, and compute, positioning Butterfly as the center of the imaging evolution.
• Tone is optimistic and forward-looking, emphasizing the transition from a hardware-centric company to a diversified technology platform with high-margin software and licensing revenue.
• Management highlights the successful reduction of cash burn and the strategic pivot to embedding their technology into third-party products to scale without incurring the capital costs of new clinical trials or market development.

Analyst Questions and Answers:

• Question: How does the enterprise business scale compared to small deals?
  • Answer: Deals are now multi-departmental and multi-year, creating an annuity-like revenue stream, though recognition is smoothed over implementation; the "groundswell" effect of doctor adoption forces system-wide contracts.
• Question: What is the trajectory of the embedded chip business?
  • Answer: It is viewed as the largest change; while current partners are early-stage, the strategy is to scale with partner volume, with potential for commercial revenue to dwarf POCUS soon.
• Question: How does Butterfly protect its IP from competitors copying the chip?
  • Answer: Protection comes from continuous innovation (4th-gen chip launching next quarter), superior image quality over legacy tech, and the complexity of the manufacturing ecosystem (TSMC partnership) and patent portfolio.
• Question: What is the capital allocation strategy?
  • Answer: Priority is organic growth in new markets, with M&A as an optionality given the strong balance sheet; potential for returning capital to shareholders in the future.

Other Key Points:

• The "Compass" software platform is critical for enterprise success, as it solves the data fragmentation issue, allowing hospitals to integrate POCUS data into existing EMRs and billing systems.
• Butterfly is actively training nurses in non-clinical settings (e.g., nursing homes) to perform specific scans (pulmonary congestion, bladder) to prevent sepsis and reduce admissions, creating a new reimbursement and value-based care model.
• The company has sold over 200,000 devices to approximately 80,000 active users, providing a large installed base for software upselling and AI partner integration.
• Management notes that many of their licensing partners approached Butterfly voluntarily, indicating strong market demand for their semiconductor technology before active sales efforts began.